

ACTIVE LEARNING TEMPLATE: *Medication*

STUDENT NAME _____

MEDICATION _____ REVIEW MODULE CHAPTER _____

CATEGORY CLASS _____

PURPOSE OF MEDICATION

Expected Pharmacological Action

Neutralizes and prevents the activity of tumor necrosis factor-alpha, resulting in anti-inflammatory and antiproliferative activity

Therapeutic Use

Decreased signs and symptoms and induction and maintenance of clinical remission in Crohn's disease. Reduction in number of fistulas and maintenance of closure of fistulae in Crohn's disease. Decreased signs and symptoms in ankylosing spondylitis.

Complications

arrhythmias, chest pain, edema, HF, hypertension, hypotension, MI, pericardial effusion, tachycardia, vasculitis, abdominal pain, nausea, vomiting, constipation, diarrhea, fatigue, headache

Medication Administration

Administer for 2 hours
Dilute with NS
Do not administer concurrently in same line as any other agents

Contraindications/Precautions

Hypersensitivity to infliximab, murine proteins, or other components in the formulation; Moderate to severe HF
History of chronic or recurrent infection or underlying illness/treatment predisposing to infection

Nursing Interventions

Assess for infusion-related reactions (fever, chills) during and for 2 hr after infusion.
Monitor patients who develop a new infection while taking infliximab closely.

Interactions

Concurrent use with anakinra or abatacept increased risk of serious infections. Concurrent use with azathioprine or methotrexate may increase risk of HSTCL. Use of live-virus vaccines or therapeutic infectious agents may increase risk of infection.

Client Education

May cause dizziness. Avoid driving or other activities requiring alertness until response to medication is known.
Advise patient that adverse reactions
Instruct patient to notify HCP with any OTC medications, being taken.

Evaluation of Medication Effectiveness

Decrease in the signs and symptoms of Crohn's disease and a decrease in the number of draining enterocutaneous fistulas. Decreased symptoms, maintaining remission, and mucosal healing with decreased corticosteroid use in ulcerative colitis.